高级检索
当前位置: 首页 > 详情页

CBX7, a Potential Prognostic Biomarker in Lung Adenocarcinoma

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Kunming Med Univ, Dept Thorac Surg, Affiliated Hosp 1, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China [2]Kunming Med Univ, Dept Pathol, Yunnan Canc Hosp, Yunnan Canc Ctr,Affiliated Hosp 3, Kunming 650118, Yunnan, Peoples R China [3]Kunming Yanan Hosp, Dept Nephrol, Kunming 650051, Yunnan, Peoples R China [4]Baoshan Peoples Hosp, Dept Thorac Surg, Baoshan 678000, Peoples R China
出处:
ISSN:

关键词: Zhao CBX7 LUAD prognosis biomarker immune infiltration

摘要:
Background: Lung adenocarcinoma (LUAD) is a major type of NSCLC and has high morbidity and mortality. The identification of useful prognostic biomarkers for LUAD is important. CBX7 has been reported in various cancers yet its expression level and potential roles have not been fully understood. Methods: GEPIA, Oncomine, TCGA, KM plotter and OSluca databases were used to explore the expression profile and prognostic effects of CBX7 mRNA expression in patients with LUAD. TIMER was used to explore the relationship between CBX7 and immune infiltrating cells. GSEA was used to further explore the potential biological process and pathways regulated by CBX7 in LUAD. Lastly, IHC detection of CBX7 in 95 samples was used to validate the result. Results: We found CBX7 was downregulated in LUAD in GEPIA, Oncomine and TCGA databases. TCGA, KM plotter and OSluca databases suggested that CBX7 was associated with poor clinical outcomes and low survival rate. Using TIMER, we found that CBX7 might be associated with immune infiltration. Via gene set enrichment analysis, we found that tumor-associated biological processes and signaling pathways were enriched in the CBX7 downregulated group. Using clinical samples, we found that CBX7 protein has low expression in LUAD and was associated with poor survival. Conclusion: CBX7 might serve as a promising biomarker and potential molecular target in

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 医学
小类 | 3 区 生物工程与应用微生物 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 3 区 生物工程与应用微生物 4 区 肿瘤学
JCR分区:
出版当年[2021]版:
Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q2 ONCOLOGY
最新[2023]版:
Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Kunming Med Univ, Dept Thorac Surg, Affiliated Hosp 1, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Kunming Med Univ, Dept Thorac Surg, Affiliated Hosp 1, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China [*1]Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming, 650032, Yunnan Province, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53621 今日访问量:0 总访问量:1665 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)